Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Friedhelm Raue
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Living Beings
Procedures
Sign-in to see full Profile
Network (preview)
49
Ziegler, Reinhard
33
Frank-Raue, Karin
20
Grauer, Andreas
16
Scherübl, Hans
12
Höppner, Wolfgang
10
Dralle, Henning
8
Schneider, Hans
5
Buhr, Heinz
5
Pecherstorfer, Martin
4
Lazaretti-Castro, Marise
4
Kohl, Brigitte
4
Schaaf, Ludwig
4
Schmidt-Gayk, Heinrich
4
Rondot, Susanne
4
Becker, Wolfgang
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Friedhelm Raue (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Frank-Raue Karin; Raue Friedhelm
Multiple endocrine neoplasia type 2 (MEN 2).
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():267-73.
-
2008: Rus Ramona; Haag Christine; Bumke-Vogt Christiane; Bähr Volker; Mayr Bernhard; Möhlig Matthias; Schulze Egbert; Frank-Raue Karin; Raue Friedhelm; Schöfl Christof
Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors.
The Journal of clinical endocrinology and metabolism 2008;93(12):4797-803.
-
2008: Frank-Raue Karin; Machens Andreas; Scheuba Christian; Niederle Bruno; Dralle Henning; Raue Friedhelm;
Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.
Clinical endocrinology 2008;69(2):259-63.
-
2008: Colombo-Benkmann Mario; Li Zhenpeng; Riemann Burkhard; Hengst Karin; Herbst Hermann; Keuser Roger; Gross Ute; Rondot Susanne; Raue Friedhelm; Senninger Norbert; Pützer Brigitte M; Frank-Raue Karin
Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
European journal of endocrinology / European Federation of Endocrine Societies 2008;158(6):811-6.
-
2007: Reusch J; Haag C; Raue F; Badenhoop K
Relapsing pheochromocytoma in a Chinese women caused by a novel mutation in exon 6 of the SDHB gene: a case report.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(9):616-8.
-
2007: Machens Andreas; Schaaf Ludwig; Karges Wolfram; Frank-Raue Karin; Bartsch Detlef K; Rothmund Matthias; Schneyer Ulrich; Goretzki Peter; Raue Friedhelm; Dralle Henning
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers.
Clinical endocrinology 2007;67(4):613-22.
-
2007: Schaaf L; Pickel J; Zinner K; Hering U; Höfler M; Goretzki P E; Spelsberg F; Raue F; von zur Mühlen A; Gerl H; Hensen J; Bartsch D K; Rothmund M; Schneyer U; Dralle H; Engelbach M; Karges W; Stalla G K; Höppner W
Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(8):509-17.
-
2007: Frank-Raue Karin; Fabel Michael; Delorme Stefan; Haberkorn Uwe; Raue Friedhelm
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
European journal of endocrinology / European Federation of Endocrine Societies 2007;157(2):215-20.
-
2007: Raue F; Haag Ch; Frank-Raue K
[Hyperparathyroidism-jaw tumor syndrome. A hereditary form of primary hyperparathyroidism with parathyroid carcinoma]
Deutsche medizinische Wochenschrift (1946) 2007;132(27):1459-62.
-
2007: Raue Friedhelm; Frank-Raue Karin
Primary hyperparathyroidism--what the nephrologist should know--an update.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007;22(3):696-9.
-
2007: Raue Friedhelm; Frank-Raue Karin
Multiple endocrine neoplasia type 2: 2007 update.
Hormone research 2007;68 Suppl 5():101-4.
-
2007: Frank-Raue Karin; Rondot Susanne; Schulze Egbert; Raue Friedhelm
Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Clinical laboratory 2007;53(5-6):273-82.
-
2006: Raue F; Haag C; Schulze E; Frank-Raue K
The role of the extracellular calcium-sensing receptor in health and disease.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2006;114(8):397-405.
-
2006: Frank-Raue K; Buhr H; Dralle H; Klar E; Senninger N; Weber T; Rondot S; Höppner W; Raue F
Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
European journal of endocrinology / European Federation of Endocrine Societies 2006;155(2):229-36.
-
2006: Müssig K; Kaltenbach S; Maser-Gluth C; Hartmann M F; Wudy S A; Horger M; Gallwitz B; Raue F; Häring H-U; Schulze E
Late diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2006;114(4):208-14.
-
2005: Frank-Raue Karin; Rondot Susanne; Hoeppner Wolfgang; Goretzki Peter; Raue Friedhelm; Meng Wieland
Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism.
The Journal of clinical endocrinology and metabolism 2005;90(7):4063-7.
-
2004: Machens Andreas; Schneyer Ulrich; Holzhausen Hans-Jürgen; Raue Friedhelm; Dralle Henning
Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.
Surgery 2004;136(5):1083-7.
-
2004: Frank-Raue Karin; Lorenz Angela; Haag Christine; Höppner Wolfgang; Boll Hans-Ullrich; Knorr Dietrich; Hentze Sabine; Raue Friedhelm
Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene.
European journal of endocrinology / European Federation of Endocrine Societies 2004;150(6):819-23.
-
2004: Scherübl H; Schaaf L; Raue F; Faiss S; Zeitz M
[Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1]
Deutsche medizinische Wochenschrift (1946) 2004;129(13):689-92.
-
2004: Scherübl H; Schaaf L; Raue F; Faiss S; Zeitz M
[Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1. I. Diagnosis]
Deutsche medizinische Wochenschrift (1946) 2004;129(12):630-3.
-
2004: Karges W; Dralle H; Raue F; Mann K; Reiners C; Grussendorf M; Hüfner M; Niederle B; Brabant G;
Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2004;112(1):52-8.
-
2003: Machens Andreas; Niccoli-Sire Patricia; Hoegel Josef; Frank-Raue Karin; van Vroonhoven Theo J; Roeher Hans-Dietrich; Wahl Robert A; Lamesch Peter; Raue Friedhelm; Conte-Devolx Bernard; Dralle Henning;
Early malignant progression of hereditary medullary thyroid cancer.
The New England journal of medicine 2003;349(16):1517-25.
-
2003: Frank-Raue K; Heimbach C; Rondot S; Usadel K-H; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
[Hereditary medullary thyroid carcinoma--genotype-phenotype characterization]
Deutsche medizinische Wochenschrift (1946) 2003;128(39):1998-2002.
-
2001: Brandi M L; Gagel R F; Angeli A; Bilezikian J P; Beck-Peccoz P; Bordi C; Conte-Devolx B; Falchetti A; Gheri R G; Libroia A; Lips C J; Lombardi G; Mannelli M; Pacini F; Ponder B A; Raue F; Skogseid B; Tamburrano G; Thakker R V; Thompson N W; Tomassetti P; Tonelli F; Wells S A; Marx S J
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
The Journal of clinical endocrinology and metabolism 2001;86(12):5658-71.
-
2001: Schilling T; Bürck J; Sinn H P; Clemens A; Otto H F; Höppner W; Herfarth C; Ziegler R; Schwab M; Raue F
Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.
International journal of cancer. Journal international du cancer 2001;95(1):62-6.
-
2000: Raue F
[Hyper- and hypocalcemia. 2: Hypocalcemia]
Deutsche medizinische Wochenschrift (1946) 2000;125(22):701-2.
-
2000: Raue F
[Hyper- and hypocalcemia. 1. Hypercalcemia]
Deutsche medizinische Wochenschrift (1946) 2000;125(21):667-70.
-
1999: Behr T M; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3124s-3138s.
-
1999: Behr T M; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(6):1029-44.
-
1998: Raue F
German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2.
Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie 1998;383(5):334-6.
-
1998: Hotz H G; Runkel N S; Frank-Raue K; Raue F; Buhr H J
Prophylactic thyroidectomy in MEN IIA: does the calcitonin level correlate with tumor spread?
Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie 1998;383(2):170-3.
-
1998: Raue F
Increased incidence of cardiovascular diseases in primary hyperparathyroidism--a cause for more aggressive treatment?
European journal of clinical investigation 1998;28(4):277-8.
-
1998: Behr T M; Jenner N; Radetzky S; Béhe M; Gratz S; Yücekent S; Raue F; Becker W
Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.
European journal of nuclear medicine 1998;25(4):424-30.
-
1998: Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter M M; Höppner W
A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
The Journal of clinical endocrinology and metabolism 1998;83(3):770-4.
-
1998: Grauer A; Raue F; Ziegler R
Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1998;106(4):353-9.
-
1998: Raue F
Routine calcitonin determination in thyroid nodules--an effective approach?
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1998;106(4):289-91.
-
1997: Behr T M; Wulst E; Radetzky S; Blumenthal R D; Dunn R M; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Cancer research 1997;57(23):5309-19.
-
1997: Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
[Mutations of ret-proto-oncogene in thyroid medullary carcinoma]
Deutsche medizinische Wochenschrift (1946) 1997;122(6):143-9.
-
1997: Frank-Raue K; Höppner W; Buhr H; Herfarth C; Raue F
Results and follow-up in eleven MEN 2A gene carriers after prophylactic thyroidectomy.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1997;105 Suppl 4():76-8.
-
1996: Frank-Raue K; Kratt T; Höppner W; Buhr H; Ziegler R; Raue F
Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene.
European journal of endocrinology / European Federation of Endocrine Societies 1996;135(2):222-5.
-
1996: Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart H F; Ritter M M; Hampel R; Klempa J; Scholz G H; Raue F
Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
The Journal of clinical endocrinology and metabolism 1996;81(5):1780-3.
-
1996: Schilling T; Pecherstorfer M; Blind E; Kohl B; Wagner H; Ziegler R; Raue F
Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model.
Bone 1996;18(4):315-9.
-
1996: Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
Application of genetic screening in families with hereditary medullary thyroid carcinoma.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1996;104 Suppl 4():108-10.
-
1996: Zink-Lorenz A; Komitowska J; Raue F
Norepinephrine induced calcitonin secretion in rat medullary thyroid carcinoma 6-23 cells: interaction between intracellular calcium and cAMP.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1996;104(1):43-9.
-
1995: Frilling A; Dralle H; Eng C; Raue F; Broelsch C E
Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Surgery 1995;118(6):1099-103; discussion 1103-4.
-
1995: Raue F; Kraimps J L; Dralle H; Cougard P; Proye C; Frilling A; Limbert E; Llenas L F; Niederle B
Primary hyperparathyroidism in multiple endocrine neoplasia type 2A.
Journal of internal medicine 1995;238(4):369-73.
-
1995: Lazaretti-Castro M; Grauer A; Baier R; Vieira J G; Ziegler R; Raue F
1,25-Dihydroxyvitamin D3 stimulates growth and inhibits calcitonin secretion in a human C cell carcinoma cell line.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 1995;28(9):1013-8.
-
1995: Zink A; Scherübl H; Höflich M; Hescheler J; Raue F
Adenosine A1-receptors inhibit cAMP and Ca2+ mediated calcitonin secretion in C-cells.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1995;27(9):408-14.
-
1995: Grauer A; Baier R; Ziegler R; Raue F
Crucial role of c-myc in 1,25(OH)2D3 control of C-cell-carcinoma proliferation.
Biochemical and biophysical research communications 1995;213(3):922-7.
-
1995: Lohr F; Bahner M L; Raue F
[Abdominal space-occupying lesion. Bilateral pheochromocytoma in MEN IIa and well differentiated retroperitoneal liposarcoma]
Der Radiologe 1995;35(8):543-5.
-
1995: Grauer A; Schroth J; Ziegler R; Raue F
Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma.
Thyroid : official journal of the American Thyroid Association 1995;5(4):287-91.
-
1995: Frilling A; Höppner W; Eng C; Mulligan L; Raue F; Broelsch C E
Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2.
Journal of molecular medicine (Berlin, Germany) 1995;73(5):229-33.
-
1995: Frank-Raue K; Bihl H; Dörr U; Buhr H; Ziegler R; Raue F
Somatostatin receptor imaging in persistent medullary thyroid carcinoma.
Clinical endocrinology 1995;42(1):31-7.
-
1995: Schilling T; Blind E; Baier R; Sinn H P; Moallem E; Silver J; Ziegler R; Raue F
Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the Walker carcinosarcoma 256 rat model.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1995;10(1):7-16.
-
1995: Grauer A; Ziegler R; Raue F
Clinical significance of antibodies against calcitonin.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1995;103(6):345-51.
-
1994: Baier R; Grauer A; Lazaretti-Castro M; Ziegler R; Raue F
Differential effects of 1,25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression.
Endocrinology 1994;135(5):2006-11.
-
1994: Raue F; Grauer A
[Therapy of hyperparathyroidism]
Medizinische Klinik (Munich, Germany : 1983) 1994;89(9):487-93.
-
1994: Pecherstorfer M; Schilling T; Blind E; Zimmer-Roth I; Baumgartner G; Ziegler R; Raue F
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
The Journal of clinical endocrinology and metabolism 1994;78(5):1268-70.
-
1994: Grauer A; Frank-Raue K; Schroth J; Raue F; Ziegler R
[Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease]
Deutsche medizinische Wochenschrift (1946) 1994;119(14):507-10.
-
1994: Raue F; Frank-Raue K; Grauer A
Multiple endocrine neoplasia type 2. Clinical features and screening.
Endocrinology and metabolism clinics of North America 1994;23(1):137-56.
-
1994: Schaaf L; Nies G; Raue F; Tuschy U; Seif F J; Trojan J; Usadel K U
[Diagnosis, therapy and screening of multiple endocrine neoplasia type I (MEN I) in four endocrinologic centers]
Medizinische Klinik (Munich, Germany : 1983) 1994;89(1):1-6.
-
1994: Raue F
Epidemiological aspects of hypercalcemia of malignancy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1994;137():99-106.
-
1994: Raue F; Pecherstorfer M
Drug therapy of hypercalcemia due to malignancy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1994;137():138-60.
-
1993: Grauer A; Reinel H H; Lunghall S; Lindh E; Ziegler R; Raue F
Formation of neutralizing antibodies after treatment with human calcitonin.
The American journal of medicine 1993;95(4):439-42.
-
1993: Grauer A; Reinel H H; Ziegler R; Raue F
Neutralizing antibodies against calcitonin.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1993;25(9):486-8.
-
1993: Raue F; Zink A; Scherübl H
Regulation of calcitonin secretion in vitro.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1993;25(9):473-6.
-
1993: Raue F; Zink A; Scherübl H
[The role of somatostatin on the cellular level]
Medizinische Klinik (Munich, Germany : 1983) 1993;88(8):492-5.
-
1993: Blind E; Raue F; Kienle P; Schroth J; Grauer A; Kabay A; Brügger P; Ziegler R
Development and validation of an assay to measure bioactivity of human calcitonin in vitro using T47D cell membranes.
Analytical biochemistry 1993;212(1):91-7.
-
1993: Raue F; Blind E
[Parathyroid hormone-related protein. A new calcium regulating hormone and its significance in tumor-associated hypercalcemia]
Deutsche medizinische Wochenschrift (1946) 1993;118(24):916-20.
-
1993: Dörr U; Frank-Raue K; Raue F; Sautter-Bihl M L; Guzman G; Buhr H J; Bihl H
The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma.
Nuclear medicine communications 1993;14(6):439-45.
-
1993: Schneider H G; Raue F; Koppold A; Ruf W; Ziegler R
Homologous desensitization of calcitonin receptors and calcitonin-dependent adenylate cyclase in T47D cells.
Acta endocrinologica 1993;128(4):373-8.
-
1993: Blind E; Raue F; Meinel T; Pecherstorfer M; Räth U; Schmidt-Gayk H; Kohl B; Ziegler R
[Diagnostic significance of parathyroid hormone-related protein in tumor patients with hypercalcemia]
Deutsche medizinische Wochenschrift (1946) 1993;118(10):330-5.
-
1993: Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
The Journal of clinical endocrinology and metabolism 1993;76(3):801-3.
-
1993: Scherübl H; Kleppisch T; Zink A; Raue F; Krautwurst D; Hescheler J
Major role of dihydropyridine-sensitive Ca2+ channels in Ca(2+)-induced calcitonin secretion.
The American journal of physiology 1993;264(3 Pt 1):E354-60.
-
1993: Blind E; Raue F; Meinel T; Bucher M; Manegold C; Ebert W; Vogt-Moykopf I; Ziegler R
Levels of parathyroid hormone-related protein in hypercalcemia of malignancy: comparison of midregional radioimmunoassay and two-site immunoradiometric assay.
The Clinical investigator 1993;71(1):31-6.
-
1993: Blind E; Raue F; Meinel T; Wüster C; Ziegler R
Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1993;25(1):40-4.
-
1993: Raue F; Geiger S; Buhr H; Frank-Raue K; Ziegler R
[The prognostic importance of calcitonin screening in familial medullary thyroid carcinoma]
Deutsche medizinische Wochenschrift (1946) 1993;118(3):49-52.
-
1993: Raue F; Kotzerke J; Reinwein D; Schröder S; Röher H D; Deckart H; Höfer R; Ritter M; Seif F; Buhr H
Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register.
The Clinical investigator 1993;71(1):7-12.
-
1993: Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr H J; Bihl H
Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study.
Hormone and metabolic research. Supplement series 1993;27():48-55.
-
1993: Frank-Raue K; Ziegler R; Raue F
The use of octreotide in the treatment of medullary thyroid carcinoma.
Hormone and metabolic research. Supplement series 1993;27():44-7.
-
1993: Blind E; Raue F; Knappe V; Schroth J; Ziegler R
Cyclic AMP formation in rat bone and kidney cells is stimulated equally by parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34.
Experimental and clinical endocrinology 1993;101(3):150-5.
-
1992: Zink A; Blind E; Raue F
Determination of serum calcitonin by immunometric two-site assays in normal subjects and patients with medullary thyroid carcinoma.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1992;30(12):831-5.
-
1992: Blind E; Raue F; Götzmann J; Schmidt-Gayk H; Kohl B; Ziegler R
Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy.
Clinical endocrinology 1992;37(3):290-7.
-
1992: Zink A; Scherübl H; Kliemann D; Höflich M; Ziegler R; Raue F
Inhibitory effect of somatostatin on cAMP accumulation and calcitonin secretion in C-cells: involvement of pertussis toxin-sensitive G-proteins.
Molecular and cellular endocrinology 1992;86(3):213-9.
-
1992: Kasperk C; Buhr H; Raue F; Hofmann W; Lorenz D; Ziegler R
[Endocrinously active parathyroid cysts. Their diagnosis by the determination of intact parathormone in the cyst fluid]
Deutsche medizinische Wochenschrift (1946) 1992;117(28-29):1093-6.
-
1992: Wüster C; Raue F; Meyer C; Bergmann M; Ziegler R
Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density.
The Journal of endocrinology 1992;134(1):141-7.
-
1992: Mekonnen Y; Raue F; Ziegler R
In vitro secretion of calcitonin from a rat C cell line: effect of repetitive stimulation with the calcium channel agonist BAY K 8644.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1992;24(6):272-5.
-
1992: Raue F; Zink A
Measurement of free cytosolic calcium in single cells: method and application.
Methods and findings in experimental and clinical pharmacology 1992;14(4):327-32.
-
1992: Grauer A; Raue F; Reinel H H; Schneider H G; Schroth J; Kabay A; Brügger P; Ziegler R
A new in vitro bioassay for human calcitonin: validation and comparison to the rat hypocalcemia bioassay.
Bone and mineral 1992;17(1):65-74.
-
1992: Blind E; Raue F; Klaiber T; Zink A; Schroth J; Buhr H; Ziegler R
Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma.
Journal of endocrinological investigation 1992;15(2):93-8.
-
1992: Scherübl H; Hescheler J; Schultz G; Kliemann D; Zink A; Ziegler R; Raue F
Inhibition of Ca(2+)-induced calcitonin secretion by somatostatin: roles of voltage dependent Ca2+ channels and G-proteins.
Cellular signalling 1992;4(1):77-85.
-
1992: Blind E; Knappe V; Raue F; Pfeilschifter J; Ziegler R
Tumor necrosis factor alpha inhibits the stimulatory effect of the parathyroid hormone-related protein on cyclic AMP formation in osteoblast-like cells via protein kinase C+.
Biochemical and biophysical research communications 1992;182(1):341-7.
-
1992: Frank-Raue K; Raue F; Buhr H J; Baldauf G; Lorenz D; Ziegler R
Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization.
Thyroid : official journal of the American Thyroid Association 1992;2(2):113-7.
-
1992: Raue F; Blind E; Grauer A
PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinoma.
Henry Ford Hospital medical journal 1992;40(3-4):296-8.
-
1992: Raue F
Epidemiology of medullary thyroid carcinoma.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1992;125():47-54.
-
1992: Raue F
Postsurgical follow-up and management.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1992;125():197-211.
-
1992: Raue F; Zink A; Scherübl H
Regulation of calcitonin secretion and calcitonin gene expression.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1992;125():1-18.
-
1992: Raue F; Zink A
Clinical features of multiple endocrine neoplasia type 1 and type 2.
Hormone research 1992;38 Suppl 2():31-5.
-
1992: Zink A; Scherubl H; Raue F; Ziegler R
Somatostatin acts via a pertussis toxin-sensitive mechanism on calcitonin secretion in C-cells.
Henry Ford Hospital medical journal 1992;40(3-4):289-92.
-
1992: Blind E; Schmidt-Gayk H; Sinn H P; O'Connor D T; Raue F
Chromogranin A as tumor marker in medullary thyroid carcinoma.
Thyroid : official journal of the American Thyroid Association 1992;2(1):5-10.
-
1991: Lazaretti-Castro M; Grauer A; Mekonnen Y; Raue F; Ziegler R
Effects of 17 beta-estradiol on calcitonin secretion and content in a human medullary thyroid carcinoma cell line.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1991;6(11):1191-5.
-
1991: Zink A; Raue F; Hoffmann R; Ziegler R
Papillary carcinoma in an ectopic thyroid.
Hormone research 1991;35(2):86-8.
-
1991: Wüster C; Schurr W; Scharla S; Raue F; Minne H W; Ziegler R
Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers.
European journal of clinical pharmacology 1991;41(3):211-5.
-
1990: Blind E; Raue F; Zisterer A; Kohl B; Ziegler R
[Epidemiology of hypercalcemia. Significance of the determination of intact parathyroid hormone for differential diagnosis]
Deutsche medizinische Wochenschrift (1946) 1990;115(46):1739-45.
-
1990: Grauer A; Raue F; Gagel R F
Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma.
Endocrinology and metabolism clinics of North America 1990;19(3):613-35.
-
1990: Buhr H J; Lehnert T; Raue F
New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1990;16(4):366-9.
-
1990: Lazaretti-Castro M; Grauer A; Raue F; Ziegler R
1,25-Dihydroxyvitamin D3 suppresses dexamethasone effects on calcitonin secretion.
Molecular and cellular endocrinology 1990;71(3):R13-8.
-
1990: Scherübl H; Raue F; Ziegler R
[Combination therapy with adriamycin, cisplatin and vindesine in C cell carcinoma of the thyroid]
Onkologie 1990;13(3):198-202.
-
1990: Grauer A; Raue F; Schneider H G; Frank-Raue K; Ziegler R
In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1990;5(4):387-91.
-
1990: Leidig G; Minne H W; Sauer P; Wüster C; Wüster J; Lojen M; Raue F; Ziegler R
A study of complaints and their relation to vertebral destruction in patients with osteoporosis.
Bone and mineral 1990;8(3):217-29.
-
1990: Schneider H G; Raue F; Bollenbach N; Scherübl H; Ziegler R
Internalization of calcitonin receptors in primary rat kidney cell cultures.
Acta endocrinologica 1990;122(2):255-62.
-
1990: Scherübl H; Raue F; Ziegler R
Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.
Journal of cancer research and clinical oncology 1990;116(1):21-3.
-
1990: Raue F; Schneider H G; Ziegler R
The calcitonin receptor: characterization and processing.
Progress in clinical and biological research 1990;332():67-79.
-
1989: Eckert R W; Scherübl H; Petzelt C; Raue F; Ziegler R
Rhythmic oscillations of cytosolic free calcium in rat C-cells.
Molecular and cellular endocrinology 1989;64(2):267-70.
-
1989: Raue F; Serve H; Grauer A; Rix E; Scherübl H; Schneider H G; Ziegler R
Role of voltage-dependent calcium channels in secretion of calcitonin from human medullary thyroid carcinoma cells.
Klinische Wochenschrift 1989;67(12):635-9.
-
1989: Scherübl H; Raue F; Zopf G; Hoffmann J; Ziegler R
Reversible desensitization of calcitonin secretion by repetitive stimulation with calcium.
Molecular and cellular endocrinology 1989;63(1-2):263-6.
-
1989: Raue F; Ziegler R
[Internal medicine aspects of endocrine tumors. The hypophysis, epithelial bodies and adrenal glands]
Der Radiologe 1989;29(1):1-6.
-
1989: Meybier H; Schmidt-Gayk H; Buhr H; Raue F
Postoperative pentagastrin-stimulated serum calcitonin concentrations in patients with medullary thyroid carcinoma: reoperations in patients with concentrations bordering the detection limit.
Henry Ford Hospital medical journal 1989;37(3-4):138-40.
-
1989: Scherübl H; Raue F; Zopf G; Ziegler R
Calcitonin secretion and cyclic AMP-efflux from C-cells, stimulated by glucagon and either calcium or Bay K 8644.
Hormone and metabolic research. Supplement series 1989;21():18-21.
-
1988: Schneider H G; Minne H W; Raue F; Fichtner H J; Baldauf G; Ziegler R
[Extraosseous calcification in juvenile dermatomyositis. The ineffectiveness of EHDP]
Deutsche medizinische Wochenschrift (1946) 1988;113(33):1279-82.
-
1988: Schneider H G; Raue F; Zink A; Koppold A; Ziegler R
Down-regulation of calcitonin receptors in T47D cells by internalization of calcitonin-receptor complexes.
Molecular and cellular endocrinology 1988;58(1):9-15.
-
1988: Raue F; Wieland U; Weiler C; Ziegler R
Enhanced calcitonin secretion in the rat after parathyroidectomy and during chronic calcium deprivation.
European journal of clinical investigation 1988;18(3):284-9.
-
1987: Raue F; Serve H; Rix E; Ziegler R
In vitro secretion of peptides of the calcitonin family: calcitonin, katacalcin, and calcitonin gene-related peptide.
Henry Ford Hospital medical journal 1987;35(2-3):143-6.
-
1987: Grauer A; Raue F; Rix E; Tschahargane C; Ziegler R
Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker.
Journal of cancer research and clinical oncology 1987;113(6):599-602.
Sign-in to see more
